Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, University of Manchester, Manchester, UK.
Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, University of Manchester, Manchester, UK.
Osteoarthritis Cartilage. 2016 Sep;24(9):1509-17. doi: 10.1016/j.joca.2016.04.018. Epub 2016 Apr 30.
International guidelines recommend intra-articular steroid injections (IASIs) in the management of hip osteoarthritis (OA), though these recommendations are extrapolated primarily from studies of knee OA. The aim of this systematic review was to assess the efficacy of IASI on pain in hip OA.
MEDLINE, EMBASE, AMED, CINAHL Plus, Web of Science and the Cochrane Central Register of Controlled Trials were searched to May 2015. Randomised controlled trials (RCTs) assessing the efficacy of hip IASI on pain were included. Pre-specified data was extracted using a standardised form. Quality was assessed using the Jadad score.
Five trials met the inclusion criteria. All had a small number of participants (≤101). All studies reported some reduction in pain at 3-4 weeks post-injection compared to control. Based on data from individual trials the treatment effect size was large at 1 week post-injection but declined thereafter. A significant (moderate effect size) reduction in pain was reported in two trials up to 8 weeks following IASI. Pooled results of two trials (n = 90) showed an increased likelihood of meeting the Outcome measures in Rheumatology Clinical Trials (OMERACT)-Osteoarthritis Research Society International (OARSI) response criteria at 8 weeks post-IASI, odds ratio 7.8 (95% confidence interval (CI): 2.7-22.8). The number needed to treat to achieve one OMERACT-OARSI responder at 8 weeks post-injection was 2.4 (95% CI: 1.7-4.2). Hip IASI appear to be generally well tolerated.
Hip IASI may be efficacious in short-term pain reduction in those with hip OA though the quality of the evidence was relatively poor. Further large, methodologically rigorous trials are required to verify whether intra-articular corticosteroids are beneficial and for how long.
国际指南建议在髋骨关节炎(OA)的治疗中采用关节内类固醇注射(IASIs),尽管这些建议主要是从膝骨关节炎的研究中推断出来的。本系统评价的目的是评估 IASI 对髋 OA 疼痛的疗效。
检索了 MEDLINE、EMBASE、AMED、CINAHL Plus、Web of Science 和 Cochrane 对照试验中心注册数据库,检索时间截至 2015 年 5 月。纳入了评估 IASI 对髋骨关节炎疼痛疗效的随机对照试验(RCTs)。使用标准化表格提取预先指定的数据。使用 Jadad 评分评估质量。
符合纳入标准的有 5 项研究。所有研究的参与者人数都较少(≤101 人)。所有研究均报告称,与对照组相比,注射后 3-4 周疼痛有所减轻。基于个别试验的数据,注射后 1 周的治疗效果较大,但此后逐渐下降。两项研究报告称,在 IASI 后 8 周内,疼痛有明显(中等效果大小)减轻。两项试验(n=90)的汇总结果显示,在 IASI 后 8 周时,更有可能符合风湿病临床疗效测量(OMERACT)-骨关节炎研究协会国际(OARSI)反应标准,比值比为 7.8(95%置信区间(CI):2.7-22.8)。在 IASI 注射后 8 周时,需要治疗的人数(NNT)为 2.4(95%CI:1.7-4.2),才能达到一个 OMERACT-OARSI 应答者。髋关节 IASI 通常耐受性良好。
在髋 OA 患者中,IASIs 可能在短期减轻疼痛方面有效,尽管证据质量相对较差。需要进一步进行大型、方法严谨的试验来验证关节内皮质类固醇是否有益以及能持续多长时间。